If hypersensitivity to the active substance or to any of the excipients is known or suspected, do not
use this product.
The safety has not been established in puppies less than 8 weeks old and/or dogs weighing
less than 2 kg. The safety has not been established for treatment with this product when
administered at intervals shorter than 8 weeks.
Please consult your veterinarian for advice before using Bravecto if your pet is receiving
medication such as non-steroidal anti-inflammatory drugs (NSAIDs) or warfarin. Studies on
Bravecto have shown no interactions with routinely used veterinary medicinal products. Fluralaner
exhibits a high plasma protein binding capacity. In vitro studies have shown fluralaner to have no
influence on the plasma protein binding capacity of carprofen and warfarin.
Safety has been demonstrated in breeding, pregnant and lactating animals treated with overdoses
of up to 3 times the maximum recommended dose. Safety has been demonstrated in puppies
aged 8-9 weeks and weighing 2.0-3.6 kg treated with overdoses of up to 5 times the maximum
recommended dose on three occasions at shorter intervals than recommended (8-week intervals).
The product was well tolerated in MDR1-deficient Collies following single oral administration at 3
times the recommended dose.
Mild and transient gastrointestinal symptoms such as diarrhoea/ vomiting/ inappetence/ drooling
related to the route of administration of the product may be observed. If you notice any serious
effects or other effects not mentioned in this leaflet, please inform your veterinarian.